NOVEL ORAL RAPID-ACTING NEUROACTIVE STEROID FOR TREATMENT OF POSTPARTUM DEPRESSION: A PLACEBO-CONTROLLED PHASE 3 CLINICAL TRIAL OF LPCN 1154A

Background

Postpartum depression (PPD), a potentially life-threatening condition, affects 10-20% of new mothers, negatively impacts maternal-infant bonding, maternal mental health, and child development. Treatment options for PPD remain limited, underscoring a clear unmet need for a rapid-acting antidepressant with superior tolerability. LPCN 1154A is an investigational oral neuroactive steroid and positive allosteric modulator of the GABAA receptor being developed as a short-duration (48-hour), at-home treatment designed to provide rapid and sustained antidepressant effects in women with PPD. This Phase 3 trial aimed to evaluate the efficacy, safety, and tolerability of LPCN 1154A in women with PPD.

Methods

This randomized, double-blind, placebo-controlled Phase 3 study (NCT06979544) enrolled women aged 15–45 years with DSM-5–defined major depressive disorder with a peripartum onset and 17-item Hamilton Depression Rating Scale (HAM-D) ≥26. Participants were randomized 1:1 to receive LPCN 1154A or matching placebo for a 48hr at-home treatment period. Antidepressant effects were evaluated with respect to both rapid onset (at 12, 36, and 60 hours) and durability of response (on Days 7 and 30).” The primary endpoint was change from baseline in total HAM-D scores at hour 60, with secondary assessments including Montgomery-Åsberg Depression Rating Scale (MADRS) and Patient Global Index of Change to capture broader symptom domains and patient-reported improvement.

Results

At the time of this submission, all participants have completed study procedure, with 90 individuals randomized (mean ±SD age: 31±6 yrs; BMI 30±6 kg/m2) and the dataset remains blinded. The randomized cohort was predominately White (64%), followed by Black/African American (32%), and other racial groups (3%), with 62% identifying as Hispanic or Latino. The mean interval between delivery and Day 1 of treatment was 26±15 weeks. Baseline HAM-D total score was 28±3 and was not significantly different by race, ethnicity, parity, delivery method of current pregnancy, nor concomitant antidepressant use. These same participants were classified by MADRS as moderate (20–34; n=32, 36%) or severe ( > 34; n=58, 64%), with the severe group showing significantly higher scores on most items (9/10). There have been no reports of drug discontinuations, excessive sedation, loss of consciousness, or serious adverse events (SAEs) related to the study drug.

Conclusions

This presentation will report primary and secondary efficacy outcomes, onset of antidepressant response, durability through Day 30, and detailed safety findings. As a novel, rapid-acting, short-course oral therapy for at-home administration, LPCN 1154A has the potential to address critical unmet needs in PPD and broaden the clinical application of neuroactive steroid modulation in mood disorders. Furthermore, the favorable safety profile of LPCN 1154A supports its potential to deliver a well-tolerated oral treatment option that could meaningfully expand the safety and accessibility of care in women’s mental health and related therapeutic areas. This study was supported by Lipocine Inc.